Emergent BioSolutions Inc. EBS 深 沪
已收盘 05-15 16:00:00 美东时间
7.94
-0.270
-3.29%
华盛通- 最 高8.18
- 今 开8.10
- 成交量 50.82万股
- 最 低 7.91
- 昨 收 8.21
- 总市值 40.97万
- 52周最高 14.06
- 市盈率 静 8.56
- 换手率 984.94%
- 52周最低 5.615
- 委 比 17.10%
- 总股本 5.16万
- 历史最高 137.61
- 量 比 0.75
- 振 幅 3.29%
- 历史最低 1.42
- 每 手 1
- 风险率 1.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
SAB Biotherapeutics (NASDAQ:SABS) reported first-quarter financial results on T...
05-12 20:59
汉坦病毒疫情引爆医药与生物科技股 —— 原因解析
核心要点 汉坦病毒疫情暴发后，部分医药股应声大涨。 开盘后，莫德纳（Moderna）、伊诺维奥（Inovio）、诺瓦瓦克斯（Novavax）等个股涨幅居前...
05-11 23:55
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
Emergent BioSolutions (NYSE:EBS) held its first-quarter earnings conference cal...
05-01 05:54
Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.
05-01 04:33
Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est
Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million to $720.000 million-$760.000 million vs $735.000 million estimate.
05-01 04:32
Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of $0.74 per share from
05-01 04:32
Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
Emergent BioSolutions signs $34.5M vaccine manufacturing, distribution deal
Emergent BioSolutions (EBS) entered a ~$34.5M agreement with Substipharm Biologics for JE vaccine manufacturing and distribution. The deal covers drug substance production for the IMOJEV Japanese Ence...
04-28 20:42
Emergent BioSolutions Signs ~$34.5M Agreement With Substipharm Biologics Over Drug Substance Production For Its Japanese Encephalitis Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese
04-28 20:15
Emergent BioSolutions Secures New Term Loan, Refinances Debt
An update from Emergent Biosolutions ( ($EBS) ) is now available. On April 16, ...
04-17 18:46
